{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-047944","form_type":"8-K","ticker":null,"cik":"0001764974","company_name":"Turnstone Biologics Corp.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.627785+00:00","generated_at":"2026-05-24T00:59:11.063422+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Turnstone Biologics transfers to Nasdaq Capital Market; gets 180-day extension for bid price compliance","bullets":["Turnstone Biologics received Nasdaq notice on Sep 27, 2024 for bid price below $1.00 for 30 consecutive days.","Transferred stock listing from Nasdaq Global Market to Capital Market, effective Mar 31, 2025, under same ticker TSBX.","Granted additional 180-day grace period until Sep 22, 2025 to regain compliance with minimum $1.00 bid price.","Company plans reverse stock split to meet bid price requirement, subject to stockholder vote via proxy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-047944","json":"https://secwatch.observer/filing/0000950170-25-047944.json","markdown":"https://secwatch.observer/filing/0000950170-25-047944.md","text":"https://secwatch.observer/filing/0000950170-25-047944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764974/000095017025047944/0000950170-25-047944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764974/000095017025047944/tsbx-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-24T00:59:11.063422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bb52a89da56888893de2ad9a7a44083a832fc0c","claim":"Turnstone Biologics Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"rd; Transfer of Listing. As previously reported, on September 27, 2024, Turnstone Biologics Corp. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer met the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) because the closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had a 180-calendar day grace period, or until March 26, 2025, to regai","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764974/000095017025047944/0000950170-25-047944-index.htm","confidence":0.98,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}